CD79b expression by IHC (target of polatuzumab vedotin)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CD79B-IHC |
|---|---|
| Type | Biomarker |
| Aliases | CD79b expressionЕкспресія CD79b (мішень полатузумабу ведотину) — ІГХ |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC on FFPE biopsy Unitscategorical (positive | negative); semi-quantitative scoring optional |
| Related biomarkers | None declared |
Notes
Universal B-cell receptor component — expressed on virtually all mature B-cell neoplasms (DLBCL, FL, MCL, MZL, CLL, Burkitt, plasma cell neoplasms variably). Primarily relevant as therapeutic target for polatuzumab vedotin (anti-CD79b ADC; replaces vincristine in Pola-R-CHP for DLBCL). Routine confirmation not required for polatuzumab eligibility — assumed positive on B-cell histology — but documented when negative or weak as caveat for ADC efficacy.
Used By
Biomarker
BIO-CD79B-MUTATION- CD79B mutation (ITAM domain, e.g. Y196)
Indications
IND-DLBCL-1L-POLA-R-CHP- IND-DLBCL-1L-POLA-R-CHPIND-DLBCL-2L-POLA-R-BENDAMUSTINE- IND-DLBCL-2L-POLA-R-BENDAMUSTINE
Questionnaires
QUEST-DLBCL-NOS-1L-STUB- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — first line